CAR-T Goes Off the Shelf: The End of One-Patient Manufacturing
Allogeneic CAR-T therapies aim to replace six-figure bespoke cell production with off-the-shelf donor lines.
From bespoke to batch
First-gen CAR-T harvests a patient's own cells, engineers them, and infuses them back — a weeks-long, million-dollar logistics feat. Donor-derived lines can be made in batches and given immediately.
Early allogeneic results trail autologous on durability, but graft-versus-tumour effects are narrowing the gap.
FAQs
What is "CAR-T Goes Off the Shelf: The End of One-Patient Manufacturing" about?
Allogeneic CAR-T therapies aim to replace six-figure bespoke cell production with off-the-shelf donor lines.
Who wrote "CAR-T Goes Off the Shelf: The End of One-Patient Manufacturing"?
"CAR-T Goes Off the Shelf: The End of One-Patient Manufacturing" was written by Demo Admin. Building incoffeed — a daily editorial on tech, AI, fintech and business. Co-founder & editor.
How long does it take to read "CAR-T Goes Off the Shelf: The End of One-Patient Manufacturing"?
8 min — that's the estimated reading time for "CAR-T Goes Off the Shelf: The End of One-Patient Manufacturing" at an average pace.
Where can I find more stories like "CAR-T Goes Off the Shelf: The End of One-Patient Manufacturing"?
More Biotech & Health coverage lives under the “Biotech & Health” topic on incoffeed. You can also react to this story and join the discussion below — the feed keeps serving related reads as you scroll.